NASDAQ · CMMB
Healthcare · Biotechnology
$2.16
Up+$0.09 (+4.35%)
Updated Aug 23, 2026, 12:44 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CMMB closed at $2.16 after 20 trading sessions, up 52.11% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $2.06 | $2.20 | $2.04 | $2.16 | 114.19K |
| Aug 20, 2026 | $2.06 | $2.10 | $1.95 | $2.07 | 83.36K |
| Aug 19, 2026 | $1.96 | $2.11 | $1.8801 | $2.09 | 118.77K |
| Aug 18, 2026 | $1.92 | $1.9201 | $1.87 | $1.91 | 17.21K |
| Aug 17, 2026 | $2.00 | $2.00 | $1.90 | $1.92 | 42.27K |
| Aug 14, 2026 | $1.92 | $1.92 | $1.84 | $1.91 | 21.56K |
| Aug 13, 2026 | $1.94 | $1.94 | $1.8912 | $1.90 | 16.07K |
| Aug 12, 2026 | $1.92 | $2.04 | $1.87 | $1.92 | 33.46K |
| Aug 11, 2026 | $1.91 | $1.92 | $1.86 | $1.90 | 18.12K |
| Aug 10, 2026 | $1.95 | $1.98 | $1.81 | $1.89 | 33.42K |
| Aug 7, 2026 | $1.88 | $2.035 | $1.83 | $1.93 | 137.59K |
| Aug 6, 2026 | $1.77 | $1.86 | $1.76 | $1.80 | 119.24K |
| Aug 5, 2026 | $1.69 | $1.80 | $1.675 | $1.75 | 97.77K |
| Aug 4, 2026 | $1.67 | $1.68 | $1.6018 | $1.68 | 38.59K |
| Aug 3, 2026 | $1.60 | $1.63 | $1.53 | $1.62 | 77.35K |
| Jul 31, 2026 | $1.56 | $1.58 | $1.48 | $1.55 | 29.97K |
| Jul 30, 2026 | $1.53 | $1.595 | $1.47 | $1.53 | 57.74K |
| Jul 29, 2026 | $1.42 | $1.605 | $1.405 | $1.46 | 221.15K |
| Jul 28, 2026 | $1.41 | $1.45 | $1.40 | $1.43 | 17.55K |
| Jul 27, 2026 | $1.40 | $1.44 | $1.40 | $1.42 | 25.09K |
The latest Smart Investors Daily articles mentioning CMMB.
CMMB research
Company profile and research snapshot.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 27, 2025 | Oppenheimer | Outperform | — |
| May 16, 2025 | Oppenheimer | Outperform | — |
| Feb 20, 2025 | Maxim Group | Buy | — |
| Nov 15, 2024 | Oppenheimer | Outperform | — |
| May 13, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.15) by 80 percent. This is a 25 percent increase over losses of $(0.36) per share
SeekingAlpha · Jul 9, 2026
2026-07-09. The following slide deck was published by Chemomab Therapeutics Ltd.
SeekingAlpha · Jul 8, 2026
Chemomab Therapeutics Ltd. (CMMB) M&A Call July 8, 2026 8:30 AM EDTCompany ParticipantsBarbara LindheimAdi George - Co-Founder, Chief Scientific...
Yahoo · Jul 8, 2026
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine platform designed to reduce risk and significantly increase the probability of clinical success Scipher’s AI Network Medicine platform identified CCL24 as a top-ranked therapeutic target for RA and used its proprietary data to identify a potential therapeutic response signature intended to support th
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CMMB.
